Eukaryote

Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence

Retrieved on: 
Tuesday, April 2, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Health Technology, University, Education, Molecular medicine, Disease, RL, Agilent Technologies, UC, COE, Life, Immunity, Eukaryote, Mobile phone

(NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the top-ranked public research universities in the world, today announced an innovative scientific collaboration to establish the Agilent Center of Excellence (CoE) in Cellular Intelligence .

Key Points: 
  • (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the top-ranked public research universities in the world, today announced an innovative scientific collaboration to establish the Agilent Center of Excellence (CoE) in Cellular Intelligence .
  • The Agilent CoE, located at UC San Diego’s School of Medicine, will foster collaboration and innovation among researchers from Agilent and UC San Diego, and other institutions and industry partners.
  • “We are thrilled to partner with Agilent to launch the Agilent CoE in Cellular Intelligence at UC San Diego, which will advance our understanding of the fundamental principles of life and the origin of biological complexity,” added Dr. Pradipta Ghosh, Professor of Medicine and Cellular and Molecular Medicine at UC San Diego and Founding Director of the program.
  • It combines experimental, computational, and theoretical approaches to decode the molecular and cellular mechanisms of these switch circuits and explore their implications for health and disease.

Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration

Retrieved on: 
Tuesday, March 26, 2024
Research, Legal, Medical Devices, Patent Law, Genetics, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Trade, CVC, Patent, RNA, CNIPA, Emmanuelle, University, Genomics, CRISPR, Eukaryote, Intellectual property, Cas9

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.

Key Points: 
  • ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge.
  • The decision to uphold the patent right in China follows a recent decision by the Japanese Patent Office earlier this year to uphold JP6692856, also part of the CVC portfolio1.
  • The decision by the CNIPA, fully upholding the patent, further demonstrates its validity and value as part of the patent collection for use of the CRISPR/Cas9 technology.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: “The decision by the CNIPA is testament to the strength of the foundational CVC CRISPR/Cas9 patent portfolio.

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 16-17 January 2024

Retrieved on: 
Friday, January 19, 2024
Classification, EMEA, Commission, Certification, Animal, Eukaryote, DNA, QWP, Decision-making, Meloxicam, AWP, Sheep, Dog, CEP, CVMP, IWP, Environment, Horse, Cat, The Committee, Cattle, MRL, Marketing, Committee, Guideline, Excipient, MAA, Medical device

CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus a positive opinion for a grouping of variations requiring assessment for Metacam (meloxicam), from…

Key Points: 


CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus a positive opinion for a grouping of variations requiring assessment for Metacam (meloxicam), from…

bit.bio Secures Foundational United States Patent for opti-oxTM, its Cell Programming Technology That Uses Genomic Safe Harbour Sites

Retrieved on: 
Wednesday, July 26, 2023
Science, Stem Cells, Other Science, Biotechnology, Health, Medical Devices, Health Technology, Genetics, CRISPR, Eukaryote, International Society for Stem Cell Research, Advanced Materials, Science Advances, ISSCR, KAT2B, Research, Brain, Cell, RBM3, Genetic code, Gene silencing, Transgene, Patent, Patient, Data, Clonal, The EMBO Journal, Biology, Synthetic biology, International Society, Vaccine

bit.bio, the company coding human cells for novel cures, has secured a foundational U.S. patent for opti-ox , its precision cell programming and manufacturing technology.

Key Points: 
  • bit.bio, the company coding human cells for novel cures, has secured a foundational U.S. patent for opti-ox , its precision cell programming and manufacturing technology.
  • opti-ox uses a dual genomic safe harbour approach to cell programming, and the granted U.S. patent covers the use of opti-ox to deterministically activate genetic code in any eukaryotic (cell with a nucleus) cell type.
  • The ability to produce defined human cell types with consistency and scale sets new standards in biological research.
  • Genomic safe harbour sites protect the integrity of the cell and enable faithful activation of transgenes by avoiding gene silencing.

EQS-News: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform

Retrieved on: 
Sunday, December 18, 2022
HPHA, RNA, Associate, Colorectal cancer, Antibody-drug conjugate, Research Foundation – Flanders (FWO), Antibody, School, SUNY, Carnegie, Cancer, GCC, State University of New York, ADC, Multiple myeloma, Control, Binghamton University, ISIN, FSE, ATACS, Frankfurt Stock Exchange, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Patient, B-cell lymphoma, Survival, Eukaryote, CD37, State, Immune system, Research, ATAC, Southern Tier, State university system, PSMA, RNA polymerase II, II, BCMA, Therapy, Fine chemical, Vaccine, EU, Pharmacy

Ladenburg, Germany, 16 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has entered into a research and exclusive option agreement with Binghamton University, State University of New York, Binghamton, NY, USA, related to a novel and proprietary immunostimulatory technology platform.

Key Points: 
  • Ladenburg, Germany, 16 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has entered into a research and exclusive option agreement with Binghamton University, State University of New York, Binghamton, NY, USA, related to a novel and proprietary immunostimulatory technology platform.
  • These immunostimulatory agents are synergistic with cytotoxic agents, including ADCs generated by Heidelberg Pharma’s ATAC technology.
  • The agreement was signed by the subsidiary Heidelberg Pharma Research GmbH and by The Research Foundation for The State University of New York on behalf of Binghamton University.
  • Binghamton University, also known as the State University of New York at Binghamton, is one of four doctoral granting research universities in the SUNY system.

EQS-News: Heidelberg Pharma AG: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022

Retrieved on: 
Sunday, December 18, 2022
HPHA, RNA, Phase, Colorectal cancer, Amanitin, Patient, Clinical trial, Partnership, Lymphatic system, Antibody, MDS, Safety, Cancer, Bone marrow, ADC, Multiple myeloma, Control, GCC, ISIN, FSE, ATACS, Human, Frankfurt Stock Exchange, AML, CD117, Acute myeloid leukemia, B-cell lymphoma, Magenta, Survival, Eukaryote, CD37, Myelodysplastic syndrome, ATAC, Therapy, Blood, BCMA, PSMA, RNA polymerase II, II, Pharmaceutical industry, Fine chemical, EU

Ladenburg, Germany, 14 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that initial clinical data from two Antibody Drug Conjugates (ADCs) based on the Company’s proprietary ATAC technology was presented at the ASH Annual Meeting 2022.

Key Points: 
  • Ladenburg, Germany, 14 December 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that initial clinical data from two Antibody Drug Conjugates (ADCs) based on the Company’s proprietary ATAC technology was presented at the ASH Annual Meeting 2022.
  • Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer.
  • Heidelberg Pharma AG is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.
  • ATAC® is a registered trademark of Heidelberg Pharma Research GmbH in the EU and USA.

EQS-News: Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022

Retrieved on: 
Friday, November 11, 2022
RNA transfection, BCMA, RNA polymerase II, CD37, Multiple myeloma, PSMA, ISIN, Frankfurt Stock Exchange, RNA, Antibody, Control, Eukaryote, Survival, Non-Hodgkin lymphoma, Cancer, Vaccine, Fine chemical, EU

Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer.

Key Points: 
  • Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer.
  • They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells.
  • Heidelberg Pharma AG is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.
  • ATAC is a registered trademark of Heidelberg Pharma Research GmbH in EU and USA.

Global Cell Culture Market Report 2022: Growing Demand for Biopharmaceuticals Driving Sector Forward - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022
Health, Biotechnology, RDNA, Parkinson, Fertilisation, Eukaryote, Ageing, Organic, Antibody, Genetic engineering, Growth, Biotechnology, Cell culture, Diabetes, Survival, Patient, Nutrient, Parkinson's disease, Vaccine, Cell, B cell, Mutagenesis, Alzheimer's disease, Carcinogenesis, Research, Stem cell, CAGR, Fine chemical

Therefore, the global cell culture market and its uses in the field of molecular biological research and development activities are predicted to remain a vital aspect for any further growth.

Key Points: 
  • Therefore, the global cell culture market and its uses in the field of molecular biological research and development activities are predicted to remain a vital aspect for any further growth.
  • The growing demand for biopharmaceutical items like vaccines as well as antibodies along with strong pipelines for biopharmaceuticals plus growing healthcare costs is predicted to stimulate the demand for the cell culture items.
  • The growing field of stem cell research holds the promise for the worldwide cell culture market.
  • The worldwide cell culture market has received heavy demand from the medical research section.

Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma

Retrieved on: 
Wednesday, August 10, 2022
CTX, Hepatocellular carcinoma, Eukaryote, Cancer, GLOBE, CDMO, TPD, Technology, Clinical trial, IND, SALL4, GSPT1, Patient, Therapy, Company, HCC, GTP, WSE, Contract, Ligase, Degenerative disease, Entrepreneurship, Pharmaceutical industry, Vaccine

The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023.

Key Points: 
  • The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023.
  • Following the selection of the lead drug candidate, Captor has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization.
  • In the CT-01 project, we are entering the advanced stage of preclinical development of the drug candidate, i.e.
  • Captor is progressing according to plan and will deliver on its promises to enter the clinical phase in 2023.

The Root Brands Releases its 7th product Mitochondria Defense Shield with NAD

Retrieved on: 
Saturday, August 6, 2022
MDS, Multimedia, Vitamin, Degenerative disease, K2, Phosphorus, Mitochondrion, Mineral, Vitamin K, Growth, NAD, Magnesium, Vitamin D, Absorption, Plant, Enzyme, DNA, Flavonoid, Reactive oxygen species, Vegetable, Bacteria, Ageing, Calcium, Eukaryote, Protein, Microdeletion syndrome, Quercetin, Disease

Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.

Key Points: 
  • Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.
  • Mitochondria are tiny double membrane-bound organelles found in almost every cell of all organisms except bacteria, they are known as "the powerhouse of the cell".
  • It enters the mitochondria in its oxidized form and protects mitochondria from oxidative injury.
  • Vitamin D is vital for regulating the absorption of calcium and phosphorus and facilitating normal immune system function.